Addex to Present at the BIO Investor Forum in San Francisco

Addex Pharmaceuticals /
Addex to Present at the BIO Investor Forum in San Francisco
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.

Geneva, Switzerland, October 24, 2011 - Addex Pharmaceuticals (SIX:ADXN), a
leading biopharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that Dr. Bharatt Chowrira, CEO of
Addex, will provide an update on the Company at the BIO Investor Forum to be
held at the Palace Hotel, San Francisco (October 25-26). Dr. Chowrira will
present at 9 am on Wednesday, October 26 in the Pacific Heights room.

Addex Pharmaceuticals (www.addexpharma.com) discovers and develops an emerging
class of small molecule drugs, called allosteric modulators, which have the
potential to be more specific and confer significant therapeutic advantages over
conventional "orthosteric" small molecule or biological drugs. The Company uses
its proprietary discovery platform to address receptors and other proteins that
are recognized as attractive targets for modulation of important diseases with
unmet medical needs. The Company's two lead products are being investigated in
Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to treat Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive
allosteric modulator or PAM) is being developed by our partner Janssen
Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several
preclinical programs including: GABA-BR PAM for pain, overactive bladder and
other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R
PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and
depression; and FSHR/LHR NAM for sex hormone dependent tumors & reproductive
system disorders. In addition, Addex has discovery programs to identify
allosteric modulators of: receptor tyrosine kinase (RTK) superfamily, including
TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's
and Huntington's diseases); and TNF receptor superfamily, including TNFR1 NAM
for inflammation (e.g. rheumatoid arthritis) and other diseases.

Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutic targets
to be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that
allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1,
RTK, TrkB or other therapeutics targets will be approved for sale in any market
or by any regulatory authority. Nor can there be any guarantee that allosteric
modulators of mGluR2, mGluR4, mGluR5, GABABR,  FSHR/LHR,  GLP1R, TNFR1, RTK,
TrkB or other therapeutic targets will achieve any particular levels of revenue
(if any) in the future. In particular, management's expectations regarding
allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR,  FSHR/LHR, GLP1R,
TNFR1, RTK, TrkB or other therapeutic targets could be affected by, among other
things, unexpected actions by our partners, unexpected regulatory actions or
delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals Ltd is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise, except as may be required
by applicable laws.


--- Ende der Mitteilung ---

Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz

ISIN: CH0029850754;




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Addex Pharmaceuticals via Thomson Reuters ONE

[HUG#1556905]

Relevante Links: Addex Therapeutics Ltd